AR071717A1 - Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. - Google Patents
Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.Info
- Publication number
- AR071717A1 AR071717A1 ARP090101708A ARP090101708A AR071717A1 AR 071717 A1 AR071717 A1 AR 071717A1 AR P090101708 A ARP090101708 A AR P090101708A AR P090101708 A ARP090101708 A AR P090101708A AR 071717 A1 AR071717 A1 AR 071717A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- phenyl
- cycloalkyl
- membered
- Prior art date
Links
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 title 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 title 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 13
- 239000001257 hydrogen Substances 0.000 abstract 13
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000004429 atom Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- -1 -SO2Ri Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5292608P | 2008-05-13 | 2008-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071717A1 true AR071717A1 (es) | 2010-07-07 |
Family
ID=40810786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101708A AR071717A1 (es) | 2008-05-13 | 2009-05-12 | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US8178131B2 (enExample) |
| EP (2) | EP2307409B1 (enExample) |
| JP (2) | JP5703212B2 (enExample) |
| KR (2) | KR101657856B1 (enExample) |
| CN (3) | CN109942575A (enExample) |
| AR (1) | AR071717A1 (enExample) |
| AU (1) | AU2009246402B2 (enExample) |
| BR (1) | BRPI0913580B8 (enExample) |
| CA (1) | CA2724262C (enExample) |
| CL (1) | CL2009001152A1 (enExample) |
| CO (1) | CO6321244A2 (enExample) |
| CR (1) | CR11803A (enExample) |
| CY (1) | CY1116692T1 (enExample) |
| DK (1) | DK2307409T3 (enExample) |
| ES (1) | ES2552643T3 (enExample) |
| HK (1) | HK1219950A1 (enExample) |
| HR (1) | HRP20151018T1 (enExample) |
| HU (1) | HUE026160T2 (enExample) |
| IL (1) | IL209258A (enExample) |
| MX (1) | MX2010012449A (enExample) |
| NZ (1) | NZ589318A (enExample) |
| PH (1) | PH12013501779B1 (enExample) |
| PL (1) | PL2307409T3 (enExample) |
| PT (1) | PT2307409E (enExample) |
| RS (1) | RS54358B1 (enExample) |
| RU (1) | RU2517194C2 (enExample) |
| SI (1) | SI2307409T1 (enExample) |
| TW (2) | TWI554512B (enExample) |
| UA (1) | UA111933C2 (enExample) |
| WO (1) | WO2009140320A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009089352A1 (en) | 2008-01-08 | 2009-07-16 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| JP5608098B2 (ja) | 2008-01-09 | 2014-10-15 | アレイ バイオファーマ、インコーポレイテッド | キナーゼ阻害薬としてのピラゾロピリジン |
| JP2009256298A (ja) * | 2008-03-26 | 2009-11-05 | Sumitomo Chemical Co Ltd | ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体 |
| AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| SG10201900212QA (en) * | 2009-04-11 | 2019-02-27 | Array Biopharma Inc | Checkpoint kinase 1 inhibitors for potentiating dna damaging agents |
| TWI466885B (zh) | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| US9029359B2 (en) * | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
| JP5749341B2 (ja) | 2010-08-20 | 2015-07-15 | ハチソン メディファーマ リミテッド | ピロロピリミジン化合物およびその使用 |
| WO2012074754A1 (en) * | 2010-11-16 | 2012-06-07 | Array Biopharma Inc. | Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors |
| AU2012254082B2 (en) | 2011-02-25 | 2016-12-08 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| EP2702063A1 (en) | 2011-04-29 | 2014-03-05 | Amgen Inc. | Bicyclic pyridazine compounds as pim inhibitors |
| GB201201566D0 (en) * | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
| SG11201406818VA (en) | 2012-04-23 | 2014-11-27 | Genentech Inc | Intermediates and processes for preparing compounds |
| KR20160104612A (ko) | 2013-07-26 | 2016-09-05 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조성물 |
| CN105705499B (zh) * | 2013-08-22 | 2018-10-12 | 基因泰克公司 | 用于制备化合物的方法 |
| WO2015027090A1 (en) * | 2013-08-22 | 2015-02-26 | Genentech, Inc. | Intermediates and processes for preparing compounds |
| JP6340416B2 (ja) * | 2013-09-25 | 2018-06-06 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ホスファチジルイノシトール３−キナーゼ−ガンマの選択的インヒビター |
| AU2015240465B2 (en) | 2014-04-04 | 2020-02-27 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| TW201613919A (en) | 2014-07-02 | 2016-04-16 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| MA41599A (fr) * | 2015-02-26 | 2018-01-02 | Array Biopharma Inc | Formes cristallines d'un composé pyrrolopyridine |
| CN107708414B (zh) | 2015-06-30 | 2022-02-25 | 首尔伟傲世有限公司 | 适用紫外线发光二极管的捕虫器 |
| RU2765154C2 (ru) * | 2015-11-04 | 2022-01-26 | Мерк Патент Гмбх | Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью |
| AU2016378579A1 (en) * | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| KR102436430B1 (ko) | 2016-06-10 | 2022-08-24 | 비타이 파마슈티컬즈, 엘엘씨 | 메닌-mll 상호 작용의 억제제 |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| CN112839648B (zh) | 2018-06-07 | 2025-04-04 | 达萨玛治疗公司 | Sarm1抑制剂 |
| JP7566731B2 (ja) * | 2018-07-03 | 2024-10-15 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| CN109053526A (zh) * | 2018-08-13 | 2018-12-21 | 南通大学 | 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法 |
| CN108912032A (zh) * | 2018-08-13 | 2018-11-30 | 南通大学 | 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法 |
| EP3897670A4 (en) | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
| WO2020150417A2 (en) | 2019-01-17 | 2020-07-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| JP2023540673A (ja) | 2020-07-15 | 2023-09-26 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| US12152018B2 (en) | 2021-01-08 | 2024-11-26 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with STING activity |
| EP4337203A4 (en) | 2021-05-14 | 2025-04-09 | Syndax Pharmaceuticals, Inc. | INHIBITORS OF THE MENIN-MLL INTERACTION |
| CN119798252A (zh) * | 2023-10-09 | 2025-04-11 | 中国石油化工股份有限公司 | 一种制备n邻位-酰基取代的含氮杂环化合物及其缩胺合铁(ii)配合物的方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR960704887A (ko) | 1993-10-14 | 1996-10-09 | 챨스 엠. 브록 | 퀴놀리지논형 화합물 (Quinolizinone type compounds) |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| EP1254115A2 (en) | 2000-02-11 | 2002-11-06 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| WO2001079198A1 (en) | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinase |
| AU2002336462A1 (en) | 2001-09-06 | 2003-03-24 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| US6797825B2 (en) * | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| EP1537106A1 (en) | 2002-08-07 | 2005-06-08 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds |
| US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| AR042667A1 (es) | 2002-12-26 | 2005-06-29 | Taisho Pharmaceutical Co Ltd | Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico |
| AU2004220176A1 (en) | 2003-03-14 | 2004-09-23 | Astrazeneca Ab | Novel fused triazolones and the uses thereof |
| GB0308208D0 (en) * | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| GB0330042D0 (en) * | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
| GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
| EP1756108A2 (en) * | 2004-04-02 | 2007-02-28 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of rock and other protein kinases |
| EP1737845A4 (en) * | 2004-04-13 | 2010-07-21 | Synta Pharmaceuticals Corp | DISPLAY HEMMER OF IL-12 PRODUCTION |
| GB0409080D0 (en) | 2004-04-23 | 2004-05-26 | Biofocus Discovery Ltd | Compounds which interact with protein kinases |
| JP2007161585A (ja) | 2004-06-25 | 2007-06-28 | Taisho Pharmaceut Co Ltd | 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体 |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| US20090275570A1 (en) | 2005-04-06 | 2009-11-05 | Astrazeneca Ab | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors |
| ES2380795T3 (es) | 2005-05-20 | 2012-05-18 | Vertex Pharmaceuticals, Inc. | Pirrolopiridinas útiles como inhibidores de proteínas quinasas |
| JP5220414B2 (ja) * | 2005-08-30 | 2013-06-26 | 旭化成ファーマ株式会社 | スルホンアミド化合物 |
| US7776865B2 (en) | 2005-10-06 | 2010-08-17 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| BRPI0616985B1 (pt) * | 2005-10-06 | 2021-10-26 | Merck Sharp & Dohme Corp. | Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto |
| DK3184526T3 (en) | 2005-12-13 | 2019-01-14 | Incyte Holdings Corp | PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR |
| EP1979353A2 (en) | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
| DE102006005179A1 (de) | 2006-02-06 | 2007-08-09 | Merck Patent Gmbh | Aminoindazolderivate |
| DE102006005180A1 (de) | 2006-02-06 | 2007-08-09 | Merck Patent Gmbh | Indazol-heteroaryl-derivate |
| US20090253718A1 (en) | 2006-04-25 | 2009-10-08 | Astex Therapeutics Limited | Pharmaceutical Compounds |
| JP2009536620A (ja) | 2006-04-25 | 2009-10-15 | アステックス、セラピューティックス、リミテッド | 医薬組み合わせ物 |
| FI3719018T3 (fi) | 2006-04-25 | 2025-10-07 | Astex Therapeutics Ltd | Puriini- ja deatsapuriinijohdannaisia farmaseuttisina yhdisteinä |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| WO2008075007A1 (en) | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
| EA019951B1 (ru) | 2007-03-01 | 2014-07-30 | Новартис Аг | Ингибиторы киназы pim и способы их применения |
| US8618121B2 (en) * | 2007-07-02 | 2013-12-31 | Cancer Research Technology Limited | 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors |
| JP2011503084A (ja) | 2007-11-07 | 2011-01-27 | シェーリング コーポレイション | 新規の細胞周期チェックポイント調節剤およびこれらの調節剤とチェックポイント阻害剤との併用 |
| WO2009089352A1 (en) * | 2008-01-08 | 2009-07-16 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| JP5608098B2 (ja) * | 2008-01-09 | 2014-10-15 | アレイ バイオファーマ、インコーポレイテッド | キナーゼ阻害薬としてのピラゾロピリジン |
| AR071717A1 (es) * | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| US8481557B2 (en) * | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| US20140221370A1 (en) | 2010-07-09 | 2014-08-07 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| WO2012074754A1 (en) | 2010-11-16 | 2012-06-07 | Array Biopharma Inc. | Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors |
-
2009
- 2009-05-12 AR ARP090101708A patent/AR071717A1/es active IP Right Grant
- 2009-05-12 CL CL2009001152A patent/CL2009001152A1/es unknown
- 2009-05-13 JP JP2011509628A patent/JP5703212B2/ja not_active Expired - Fee Related
- 2009-05-13 CA CA2724262A patent/CA2724262C/en active Active
- 2009-05-13 HU HUE09747404A patent/HUE026160T2/en unknown
- 2009-05-13 AU AU2009246402A patent/AU2009246402B2/en not_active Ceased
- 2009-05-13 TW TW103133772A patent/TWI554512B/zh not_active IP Right Cessation
- 2009-05-13 MX MX2010012449A patent/MX2010012449A/es active IP Right Grant
- 2009-05-13 RU RU2010150786/04A patent/RU2517194C2/ru active
- 2009-05-13 PL PL09747404T patent/PL2307409T3/pl unknown
- 2009-05-13 CN CN201910068067.1A patent/CN109942575A/zh active Pending
- 2009-05-13 KR KR1020147015705A patent/KR101657856B1/ko not_active Expired - Fee Related
- 2009-05-13 RS RS20150711A patent/RS54358B1/sr unknown
- 2009-05-13 UA UAA201015012A patent/UA111933C2/uk unknown
- 2009-05-13 BR BRPI0913580A patent/BRPI0913580B8/pt not_active IP Right Cessation
- 2009-05-13 PT PT97474043T patent/PT2307409E/pt unknown
- 2009-05-13 ES ES09747404.3T patent/ES2552643T3/es active Active
- 2009-05-13 DK DK09747404.3T patent/DK2307409T3/en active
- 2009-05-13 CN CN201510289964.7A patent/CN104926810B/zh not_active Expired - Fee Related
- 2009-05-13 TW TW098115906A patent/TWI458727B/zh not_active IP Right Cessation
- 2009-05-13 HR HRP20151018TT patent/HRP20151018T1/hr unknown
- 2009-05-13 WO PCT/US2009/043691 patent/WO2009140320A1/en not_active Ceased
- 2009-05-13 NZ NZ589318A patent/NZ589318A/en not_active IP Right Cessation
- 2009-05-13 US US12/992,468 patent/US8178131B2/en active Active
- 2009-05-13 CN CN200980127299.4A patent/CN102089307B/zh not_active Expired - Fee Related
- 2009-05-13 EP EP09747404.3A patent/EP2307409B1/en active Active
- 2009-05-13 SI SI200931284T patent/SI2307409T1/sl unknown
- 2009-05-13 EP EP15175131.0A patent/EP2990407B1/en active Active
- 2009-05-13 KR KR1020107027941A patent/KR101643426B1/ko not_active Expired - Fee Related
-
2010
- 2010-11-11 IL IL209258A patent/IL209258A/en active IP Right Grant
- 2010-11-19 CR CR11803A patent/CR11803A/es unknown
- 2010-11-30 CO CO10150963A patent/CO6321244A2/es active IP Right Grant
-
2012
- 2012-03-20 US US13/425,186 patent/US8545897B2/en not_active Expired - Fee Related
-
2013
- 2013-08-23 US US13/974,895 patent/US8758830B2/en active Active
- 2013-08-28 PH PH12013501779A patent/PH12013501779B1/en unknown
-
2014
- 2014-05-06 US US14/271,129 patent/US8981085B2/en active Active
-
2015
- 2015-01-07 US US14/591,691 patent/US9365568B2/en active Active
- 2015-02-23 JP JP2015032474A patent/JP2015098482A/ja not_active Withdrawn
- 2015-09-16 CY CY20151100812T patent/CY1116692T1/el unknown
-
2016
- 2016-01-05 US US14/988,521 patent/US9969727B2/en active Active
- 2016-07-08 HK HK16107983.6A patent/HK1219950A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071717A1 (es) | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. | |
| AR079486A1 (es) | Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas. | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| PE20181894A1 (es) | Nuevos analogos de nucleosidos sustituidos para su uso como inhibidores de prmt 5 | |
| PE20200292A1 (es) | Compuestos de heteroarilo biciclicos 6-6 fusionados y su uso como inhibidores de lats | |
| PE20191540A1 (es) | DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA | |
| AR076236A1 (es) | Compuestos organicos y sus usos | |
| AR081859A1 (es) | Pirimidinas 2,4,6-trisustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de tumores sensibles a la inhibicion de la cinasa atr | |
| PE20120058A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
| PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| AR083813A1 (es) | Derivados de pirazol aminopirimidina como moduladores de lrrk2 | |
| AR071856A1 (es) | Derivados de indazoles sustituidos con fenilo o piridinilo, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides. | |
| DOP2010000022A (es) | Derivados de pirimidina 934 | |
| PE20080841A1 (es) | Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion | |
| AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
| PE20150399A1 (es) | Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| AR080187A1 (es) | Derivados pirazolicos condensados con heterociclos nitrogenados utiles en el tratamiento de enfermedades inflamatorias, inmunitarias y/o trastornos mieloploliferativos y composiciones farmaceuticas que los contienen. | |
| AR098912A1 (es) | Inhibidores de syk | |
| AR074499A1 (es) | Carboxamidas heterobiciclicas como inhibidoras de cinasas | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| AR080865A1 (es) | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. | |
| AR056979A1 (es) | Derivados de dihidrobenzofuranos y usos de los mismos | |
| PE20160240A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| PE20130157A1 (es) | Inhibidores de la polimerasa virica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FG | Grant, registration |